Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients

This publication has 69 references indexed in Scilit:

• Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies
  Cancer Cell, 2024
• Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines
  Current Opinion in Virology, 2023
• Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
  Annals of Oncology, 2022
• Loss of α-gal during primate evolution enhanced antibody-effector function and resistance to bacterial sepsis
  Cell Host & Microbe, 2021
• PEGylated immunoliposome-loaded endoglin single-chain antibody enhances anti-tumor capacity of porcine α1,3GT gene
  Biomaterials, 2019
• Development of α‐Gal–Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies
  Angewandte Chemie International Edition, 2019
• Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
  Cell, 2017
• Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma
  Cancer Immunology, Immunotherapy, 2016
• AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
  Cancer Cell, 2011
• Natural IgM antibodies: The orphaned molecules in immune surveillance
  Advanced Drug Delivery Reviews, 2006